The US Food and Drug Administration has approved ocriplasmin (Jetrea), the first pharmaceutical product for treating for symptomatic vitreomacular adhesion, which occurs when the vitreous gel of the eye fails to detach from the retina. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
